Wednesday, April 14, 2021
ADVT 
International

AstraZeneca resuming US testing of COVID-19 vaccine

Darpan News Desk The Canadian Press, 24 Oct, 2020
  • AstraZeneca resuming US testing of COVID-19 vaccine

AstraZeneca Inc. announced Friday that regulators are letting it resume testing of its COVID-19 vaccine candidate in the U.S.

Testing of the vaccine was halted worldwide early last month because of a British study volunteer’s illness. Studies have already resumed in other countries, and the British drugmaker said the Food and Drug Administration gave the company the go-ahead Friday to resume U.S. testing.

The AstraZenca vaccine, developed with Oxford University, is one of several coronavirus vaccine candidates in final-stage testing around the world.

The drugmaker said it was allowed to resume testing after the FDA “reviewed all safety data from trials globally and concluded it was safe to resume the trial.”

The company said that testing has already resumed in the United Kingdom, Brazil, South Africa and Japan.

Such temporary halts of drug and vaccine testing are relatively common, because in research involving thousands of participants, some are likely to fall ill. Putting a study on hold allows researchers to investigate whether an illness is a side effect or a coincidence.

AstraZeneca's study in the U.S. involves 30,000 people, with some getting the vaccine and others a dummy shot.

Testing was stopped after one participant in the United Kingdom developed severe neurological symptoms consistent with a rare inflammation of the spinal cord called transverse myelitis. It was the second hold in AstraZeneca testing.

MORE International ARTICLES

Lilly seeks emergency use of its antibody drug for COVID-19

Lilly seeks emergency use of its antibody drug for COVID-19

Eli Lilly and Company announced the partial results Wednesday in a news release; they have not yet been published or reviewed by independent scientists.

Lilly seeks emergency use of its antibody drug for COVID-19

Experts call Trump's rosy virus message misguided

Experts call Trump's rosy virus message misguided

The seven-day rolling average for new U.S. cases has climbed over the past two weeks to almost 42,000 per day. The nation also sees more than 700 COVID-19 deaths each day.

Experts call Trump's rosy virus message misguided

With Trump sick, all eyes on Wednesday's VP debate

With Trump sick, all eyes on Wednesday's VP debate

Questions persist about Donald Trump's health following his COVID-19 diagnosis, as well as the age of 77-year-old challenger Joe Biden.

With Trump sick, all eyes on Wednesday's VP debate

Magnitsky sanctions demanded in Iranian shootdown

Magnitsky sanctions demanded in Iranian shootdown

There were 176 people killed when the Iranian military shot down Ukraine International Airlines Flight PS752 on Jan. 8, shortly after it took off from Tehran.

Magnitsky sanctions demanded in Iranian shootdown

Berry scare: U.S. eyeing foreign produce imports

Berry scare: U.S. eyeing foreign produce imports

U.S. Trade Representative Robert Lighthizer served notice last week that the Trump administration fears domestic producers are being unfairly harmed by what they call a recent increase in berry imports from Canada and Mexico.

Berry scare: U.S. eyeing foreign produce imports

EU regulator starts safety review of coronavirus drug

EU regulator starts safety review of coronavirus drug

In a statement on Friday, the EU regulator said it isn’t clear whether remdesivir was causing the “acute kidney injury,” but that the issue “warrants further investigation.”

EU regulator starts safety review of coronavirus drug